Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.

@article{Korytkowski2002GlimepirideIB,
  title={Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.},
  author={M. Korytkowski and Abraham Thomas and Lynn Reid and M. B. Tedesco and W. Gooding and J. Gerich},
  journal={Diabetes care},
  year={2002},
  volume={25 9},
  pages={
          1607-11
        }
}
OBJECTIVE The purpose of this study was to assess the effect of glimepiride on insulin sensitivity and secretion in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS After a 2-week washout from prior sulfonylurea therapy, 11 obese subjects with type 2 diabetes underwent euglycemic and hyperglycemic clamp studies before and during glimepiride therapy. RESULTS Glimepiride resulted in a 2.4-mmol/l decrease in fasting plasma glucose (P = 0.04) that was correlated with reductions in… Expand
Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
TLDR
It is demonstrated that R is more efficient that G on improving glucose- and meal- induced insulin secretion as well as on controlling for postprandial glucose excursion. Expand
Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus.
TLDR
In this study, glimepiride achieved desirable glycemic control in patients with recent-onset type 2 DM through improvement in insulin secretion and sensitivity. Expand
Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.
TLDR
Glimepiride and metformin are effective individually in achieving a glycemic goal with a less daily insulin dose, weight gain, and hypoglycemic episodes in comparison to insulin monotherapy in subjects with type 2 diabetes mellitus with further marked reduction in these parameters when used concurrently. Expand
Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes.
TLDR
Since endogenous insulin secretion is more physiological than subcutaneous insulin injection, continuing glimepiride may remain beneficial, partly through enhancing insulin secretion, in individuals with a long duration of diabetes and basal-prandial insulin therapy. Expand
Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
TLDR
Glycaemic control was seen in all study groups, the improvement was better in drug treated groups than in the control group, and beneficial effects on lipid levels, improved insulin sensitivity and improved insulin secretion were seen. Expand
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
TLDR
Glimepiride can rapidly and stably improve glycemic control and lipoprotein metabolism, significantly alleviate insulin resistance and enhance fibrinolytic activity. Expand
Discrete effects of glimepiride and metformin on preprandial and postprandial glucose and contributions to the amelioration of chronic hyperglycemia
TLDR
Glimepiride and metformin had different effects on postprandial glucose, insulin, and the consequent change in HbA1c in type 2 diabetic patients by performing standard meal tests, before and after treatment. Expand
The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide
TLDR
Although non-significant, better second phase insulin secretion could be noted with treatment of repaglinide than gliclazide for 4 months, which is needed to solve this interesting and important question. Expand
Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
TLDR
It is suggested that long-term treatment with pioglitazone enhances insulin sensitivity relative to glimepiride in Mexican patients with type 2 diabetes and that piog litazone may have a more sustained antihyperglycemic effect. Expand
Glimepiride: evidence-based facts, trends, and observations
TLDR
Glimepiride is a second-generation sulfonylurea that stimulates pancreatic β cells to release insulin and is effective in reducing fasting plasma glucose, post-prandial glucose, and glycosylated hemoglobin levels and is a useful, cost-effective treatment option for managing type 2 diabetes mellitus. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects.
TLDR
The data indicate that sulfonylurea treatment did not improve the diminished insulin sensitivity of peripheral glucose clearance in type 1-diabetic subjects; insulin action on hepatic glucose production and lipolysis was unimpaired in diabetics and remained uninfluenced by glibornuride. Expand
Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin-dependent diabetes mellitus.
TLDR
It is indicated that tolbutamide augments first phase insulin secretion in untreated diabetics independently of the prestimulus glucose level, however, changes in the glucose level significantly modulate the sulfonylurea influence on the second phase insulin response to glucose. Expand
Influence of gliclazide on glucose-stimulated insulin release in man.
TLDR
The influence of the SU gliclazide on glucose-stimulated insulin release in eight healthy male volunteers was assessed and no difference was observed in plasma C-peptide response at the end of the 32-mmol/L hyperglycemic glucose clamps. Expand
Different Effects of Glyburide and Glipizide on Insulin Secretion and Hepatic Glucose Production in Normal and NIDDM Subjects
TLDR
The results indicate that the acute administration of GB and GZ to NIDDM subjects has quantitatively different results on hepatic glucose production and acute plasma insulin response to hyperglycemia, challenging the concept that sulfonylurea agents, when given acutely, potentiate glucose-stimulated insulin secretion. Expand
The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
  • H. E. Clark, D. Matthews
  • Medicine
  • Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
  • 1996
The comparative effects of glimepiride (Amaryl; HOE 490) and glibenclamide on insulin and glucose metabolism under hyperglycaemic and hyperinsulinaemic, euglycaemic clamp conditions were studied in aExpand
Mechanism of improvement in glucose metabolism after chronic glyburide therapy.
TLDR
The effect of glyburide on glucose metabolism was examined in non-insulin-dependent diabetic subjects (NIDDM) and 7 young, control subjects and an increase in tissue sensitivity to insulin was unassociated with any change in insulin binding to monocytes. Expand
Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study
TLDR
Sulphonylurea augments glucose-stimulated second-phase insulin secretion without changing the sensitivity of the β-cell to glucose and first- phase insulin secretion is reduced in non-insulin-dependent diabetic patients with fasting hyperglycaemia and is not influenced by glipizide. Expand
A Dose-Response Study of Glimepiride in Patients With NIDDM Who Have Previously Received Sulfonylurea Agents
TLDR
Although the 4- and 8-mg once-daily doses were significantly more potent than the 1-mg dose, all three doses yielded clinical improvement and might be beneficial for patients who are difficult to treat. Expand
Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM
TLDR
Glipizide GITS significantly improved meal tolerance, reduced glycated blood proteins, and increased insulin sensitivity in vivo, and there was no significant change in abdominal fat distribution during the trial. Expand
The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects
TLDR
Glyburide therapy increases endogenous insulin secretion, increases adipocyte insulin binding after 18, but not 3, mo of therapy, enhances peripheral insulin action by acting primarily at a post-receptor site, and reduces basal hepatic glucose output. Expand
...
1
2
3
4
...